Compare McCormick & Company, Incorporated (MKC) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Natera Inc. Common Stock — how do they compare? McCormick & Company, Incorporated trades at $45.03 (market cap $12.02B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 4.7× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays a 4.3% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 68 Days and Natera Inc. Common Stock for 0 Days on average.
| MKC | NTRA | |
|---|---|---|
Market Cap | $12.02B | $57.03B |
Volume | 3,822,006 | 1,131,157 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $425.64 |
52-Week Low | $44.14 | $179.42 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | $16.71B | $56.18B |
Dividend Yield | 4.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $44.80, down 1.71% on the day, with a bearish technical signal from moving averages. The company reported strong Q3 2026 earnings of $0.86 per share, beating estimates, driven by 17% sales growth and margin expansion. Valuation ratios appear attractive with a P/E of 8.07 and net income margin of 19.39%. Recent news highlights the acquisition of McCormick de Mexico and a reaffirmed 2026 outlook.
The stock offers value with solid profitability and dividend growth, but faces near-term technical headwinds and mixed analyst sentiment. Upside exists toward the $53.50 consensus target, though execution risks and market volatility require monitoring. The current price near support at $44 suggests a potential entry point for long-term investors.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
